organization · Reporting owner
venBio Global Strategic Fund IV, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Attovia Therapeutics, Inc.
Report date August 06, 2026 · Filed August 10, 2026
Section 16 reporting ended · disclosed 2026-08-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,181,367 |
Last balance in matching sequence
After 2026-08-06 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-08-06 · Conversion · Acquired 2,311,870 · Balance 2,311,870 F1: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Row 2 · 2026-08-06 · Conversion · Acquired 821,998 · Balance 3,133,868 F1: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Row 3 · 2026-08-06 · Conversion · Acquired 665,147 · Balance 3,799,015 F1: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Row 4 · 2026-08-06 · Purchase · Acquired 382,352 · Balance 4,181,367 F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-06 · Conversion · Disposed 21,477,273 · Balance 0 F1: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-06 · Conversion · Disposed 7,636,362 · Balance 0 F1: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-06 · Conversion · Disposed 6,179,219 · Balance 0 F1: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration.
F2: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 10, 2026 20:12 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionSeries C Preferred Stock · Derivative | 6,179,219 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003548 · form4.xml · derivative · entry 7 venBio Global Strategic Fund IV, L.P. · CIK 0001862109 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 665,147 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F1 · derivative.exercise_date: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F1 · derivative.expiration_date: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2 · ownership.direct: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:12 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionSeries B Preferred Stock · Derivative | 7,636,362 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003548 · form4.xml · derivative · entry 6 venBio Global Strategic Fund IV, L.P. · CIK 0001862109 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 821,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F1 · derivative.exercise_date: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F1 · derivative.expiration_date: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2 · ownership.direct: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:12 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionSeries A Preferred Stock · Derivative | 21,477,273 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003548 · form4.xml · derivative · entry 5 venBio Global Strategic Fund IV, L.P. · CIK 0001862109 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,311,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F1 · derivative.exercise_date: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F1 · derivative.expiration_date: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2 · ownership.direct: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:12 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | PurchaseCommon Stock | 382,352 | $17.00 | $6,499,984.00 |
DisclosureSEC source: 0000905148-26-003548 · form4.xml · nonDerivative · entry 4 venBio Global Strategic Fund IV, L.P. · CIK 0001862109 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,181,367 F2 · ownership.direct: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:12 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionCommon Stock | 665,147 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-003548 · form4.xml · nonDerivative · entry 3 venBio Global Strategic Fund IV, L.P. · CIK 0001862109 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,799,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2 · ownership.direct: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:12 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionCommon Stock | 821,998 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-003548 · form4.xml · nonDerivative · entry 2 venBio Global Strategic Fund IV, L.P. · CIK 0001862109 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,133,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2 · ownership.direct: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:12 UTC | Attovia Therapeutics, Inc. ATTO · Entity 4984 | ConversionCommon Stock | 2,311,870 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-003548 · form4.xml · nonDerivative · entry 1 venBio Global Strategic Fund IV, L.P. · CIK 0001862109 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,311,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. F2 · ownership.direct: These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.